Research ArticleOriginal Article

Prognostic value of chemotherapy-induced leukopenia in small-cell lung cancer

Wei Liu, Cui-Cui Zhang and Kai Li
Cancer Biology & Medicine June 2013, 10 (2) 92-98; DOI: https://doi.org/10.7497/j.issn.2095-3941.2013.02.005

References

  1. 1.↵
    2. Han Y,
    3. Yu Z,
    4. Wen S,
    5. Zhang B,
    6. Cao X,
    7. Wang X.
    Prognostic value of chemotherapy-induced neutropenia in early-stage breast cancer. Breast Cancer Res Treat 2012;131:483–490.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    2. Yamanaka T,
    3. Matsumoto S,
    4. Teramukai S,
    5. Ishiwata R,
    6. Nagai Y,
    7. Fukushima M.
    Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma. Br J Cancer 2007;97:37–42.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    2. Shitara K,
    3. Matsuo K,
    4. Takahari D,
    5. Yokota T,
    6. Inaba Y,
    7. Yamaura H, et al.
    Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX. Eur J Cancer 2009;45:1757–1763.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    2. Kvinnsland S.
    The leucocyte nadir, a predictor of chemotherapy efficacy? Br J Cancer 1999;80:1681.
    OpenUrlPubMed
  5. 5.↵
    2. Saarto T,
    3. Blomqvist C,
    4. Rissanen P,
    5. Auvinen A,
    6. Elomaa I.
    Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. Br J Cancer 1997;75:301–305.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.
    2. Poikonen P,
    3. Saarto T,
    4. Lundin J,
    5. Joensuu H,
    6. Blomqvist C.
    Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF. Br J Cancer 1999;80:1763–1766.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.
    2. Cameron DA,
    3. Massie C,
    4. Kerr G,
    5. Leonard RC.
    Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer. Br J Cancer 2003;89:1837–1842.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.
    2. Ishitobi M,
    3. Komoike Y,
    4. Motomura K,
    5. Koyama H,
    6. Inaji H.
    Prognostic significance of neutropenia on day one of anthracycline-based neoadjuvant chemotherapy in operable breast cancer. Oncology 2010;78:213–219.
    OpenUrlPubMed
  9. 9.↵
    2. Mayers C,
    3. Panzarella T,
    4. Tannock IF.
    Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer 2001;91:2246–2257.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    2. Nakata B,
    3. Tsuji A,
    4. Mitachi Y,
    5. Yamamitsu S,
    6. Hirata K,
    7. Takeuchi T, et al.
    Moderate neutropenia with S-1 plus low-dose cisplatin may predict a more favourable prognosis in advanced gastric cancer. Clin Oncol (R Coll Radiol) 2006;18:678–683.
    OpenUrlPubMed
  11. 11.↵
    2. Singh S,
    3. Parulekar W,
    4. Murray N,
    5. Feld R,
    6. Evans B,
    7. Tu D, et al.
    Influence of gender on treatment outcome and toxicity in small cell lung cancer (SCLC). J Clin Oncol 2004;22:abstr7041.
  12. 12.↵
    2. Di Maio M,
    3. Gridelli C,
    4. Gallo C,
    5. Shepherd F,
    6. Piantedosi FV,
    7. Cigolari S, et al.
    Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol 2005;6:669–677.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    2. Gurney H.
    How to calculate the dose of chemotherapy. Br J Cancer 2002;86:1297–1302.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.
    2. Gurney H.
    Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 1996;14:2590–2611.
    OpenUrlAbstract
  15. 15.
    2. Ratain MJ.
    Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit? J Clin Oncol 1998;16:2297–2298.
    OpenUrlPubMedWeb of Science
  16. 16.↵
    2. Sawyer M,
    3. Ratain MJ.
    Body surface area as a determinant of pharmacokinetics and drug dosing. Invest New Drugs 2001;19:171–177.
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.↵
    2. Nguyen L,
    3. Tranchand B,
    4. Puozzo C,
    5. Variol P.
    Population pharmacokinetics model and limited sampling strategy for intravenous vinorelbine derived from phase I clinical trials. Br J Clin Pharmacol 2002;53:459–468.
    OpenUrlCrossRefPubMed
  18. 18.↵
    2. Allerheiligen S,
    3. Johnson R,
    4. Hatcher B,
    5. Freeman K,
    6. Tarassoff P,
    7. Voi M, et al.
    Gemcitabine pharmacokinetics are influenced by gender, body surface area (BSA), and duration of infusion. Proc Am Soc Clin Oncol 1994;13:339.
    OpenUrl
  19. 19.↵
    2. Dobbs NA,
    3. Twelves CJ,
    4. Gillies H,
    5. James CA,
    6. Harper PG,
    7. Rubens RD.
    Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry. Cancer Chemother Pharmacol 1995;36:473–476.
    OpenUrlPubMed
  20. 20.↵
    2. Grochow LB,
    3. Ames MM.
    eds. A clinician’s guide to chemotherapy pharmacokinetics and pharmacodynamics: Williams & Wilkins, 1998.
  21. 21.↵
    2. Williamson DF.
    Descriptive epidemiology of body weight and weight change in U.S. adults. . Ann Intern Med 1993;119:646–649.
    OpenUrlCrossRefPubMedWeb of Science
  22. 22.↵
    2. Rodvold KA,
    3. Rushing DA,
    4. Tewksbury DA.
    Doxorubicin clearance in the obese. J Clin Oncol 1988;6:1321–1327.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    2. Powis G,
    3. Reece P,
    4. Ahmann DL,
    5. Ingle JN.
    Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients. Cancer Chemother Pharmacol 1987;20:219–222.
    OpenUrlCrossRefPubMedWeb of Science
  24. 24.↵
    2. Gurney HP,
    3. Ackland S,
    4. Gebski V,
    5. Farrell G.
    Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation. J Clin Oncol 1998;16:2299–2304.
    OpenUrlAbstract
  25. 25.↵
    2. Voloshin T,
    3. Gingis-Velitski S,
    4. Bril R,
    5. Benayoun L,
    6. Munster M,
    7. Milsom C, et al.
    G-CSF supplementation with chemotherapy can promote revascularization and subsequent tumor regrowth: prevention by a CXCR4 antagonist. Blood 2011;118:3426–3435.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    2. Natori T,
    3. Sata M,
    4. Washida M,
    5. Hirata Y,
    6. Nagai R,
    7. Makuuchi M.
    G-CSF stimulates angiogenesis and promotes tumor growth: potential contribution of bone marrow-derived endothelial progenitor cells. Biochem Biophys Res Commun 2002;297:1058–1061.
    OpenUrlCrossRefPubMedWeb of Science
  27. 27.↵
    2. Lyman GH,
    3. Dale DC,
    4. Crawford J.
    Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 2003;21:4524–4531.
    OpenUrlAbstract/FREE Full Text
  28. 28.
    2. Lyman GH,
    3. Dale DC,
    4. Friedberg J,
    5. Crawford J,
    6. Fisher RI.
    Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin’s lymphoma: a nationwide study. J Clin Oncol 2004;22:4302–4311.
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    2. Leonard RC,
    3. Miles D,
    4. Thomas R,
    5. Nussey F.
    Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients. Br J Cancer 2003;89:2062–2068.
    OpenUrlCrossRefPubMedWeb of Science
  30. 30.↵
    2. Bergh J.
    Tailored chemotherapy to equal toxicity: is it possible? Recent Results Cancer Res 1998;152:328–340.
    OpenUrlPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords